Open AccessThe European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Author(s) -
Gravanis Iordanis,
Tzogani Kyriaki,
Hennik Paula,
Graeff Pieter,
Schmitt Petra,
MuellerBerghaus Jan,
Salmonson Tomas,
Gisselbrecht Christian,
Laane Edward,
Bergmann Lothar,
Pignatti Francesco
Publication year - 2016
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0276
Subject(s) - brentuximab vedotin , medicine , anaplastic large cell lymphoma , cd30 , antibody drug conjugate , oncology , neutropenia , lymphoma , gastroenterology , surgery , chemotherapy , immunology , antibody , monoclonal antibody
On October 25, 2012, a conditional marketing authorization valid throughout the European Union (EU) was issued for brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). For HL, the indication is restricted to treatment after autologous stem cell transplantation (ASCT) or after at least two previous therapies when ASCT or multiagent chemotherapy is not a treatment option.